Aparna Biosciences Corporation (AparnaBio) is a privately held biotechnology company formed to pursue its passion to develop biomedical nanoparticle technology and products for research and treatment of human disease. The company is developing NanoElectroPlex, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
AparnaBio has launched its InVivoPlex – TUMOR reagent system for in vivo delivery of siRNA and gene expression plasmids for research use. AparnaBio has secured intellectual property protection for its platform technology, established laboratories, expanded its staff, and been awarded significant competitive grant funding.
The company welcomes the opportunity to engage with collaborators and partners in academia and industry to apply its technology to the in vivo delivery of novel experimental and therapeutic molecules.
Siyu Chen, Ph.D.
In this interview, we discuss a new approach to surface-enhanced Raman spectroscopy that utilizes nano-pockets to capture target molecules, ensuring a highly sensitive way to detect chemical processes.
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
This article outlines how Unity, Oxford Instruments’ new detector for a revolutionary new imaging technique, can be used to revolutionize imaging.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.